Results 1 to 10 of about 35,900 (132)

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy [PDF]

Frontiers in Radiology, 2023
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Zahra Saadatpour, C. Austin Wheeler, Marissa Natelson Love, Manoj Tanwar   +7 more
doaj   +6 more sources

Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications [PDF]

Frontiers in Neuroscience
Alzheimer’s disease (AD) affects over 6 million people over the age of 65. The advent of new anti-amyloid monoclonal antibodies as treatment for early Alzheimer’s disease these immunotherapeutics may slow disease progression but also pose significant ...
Sarah J. Doran, Russell P. Sawyer
doaj   +6 more sources

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 [PDF]

The Journal of Prevention of Alzheimer's Disease
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, Emily C. Collins, Stephen Salloway, Mark A. Mintun, John R. Sims   +13 more
doaj   +4 more sources

Spontaneous and Drug-Induced Amyloid-Related Imaging Abnormalities: Overlaps, Divergences, and Clinical Implications Across a Continuum Between Alzheimer’s Disease and Cerebral Amyloid Angiopathy [PDF]

Biomolecules
Background: Amyloid-related imaging abnormalities (ARIA) have gained significance in the context of anti-amyloid therapies (AATs), exhibiting clinical and radiological manifestations that overlap with Cerebral Amyloid Angiopathy-related inflammation (CAA-
Marialuisa Zedde, Mattia Losa, Elena Grisafi, Davide D. Lucia, Ilaria Gandoglia, Massimo Del Sette, Matteo Pardini, Luca Roccatagliata, Rosario Pascarella, Fabrizio Piazza   +9 more
doaj   +4 more sources

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics [PDF]

Brain, 2023
AbstractExcess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in the brain are a major hallmark of Alzheimer’s disease. Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target amyloid-β and have identified MRI signal abnormalities called amyloid-related imaging ...
James Nicoll, Harald Hampel, Liana Apostolova   +2 more
exaly   +4 more sources

Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment [PDF]

Pharmaceuticals
Background: Anti-amyloid therapies (AAT) are reshaping the therapeutic landscape of Alzheimer’s disease (AD), yet their implementation remains constrained by the risk of amyloid-related imaging abnormalities (ARIA).
Marialuisa Zedde, Mattia Losa, Andrea Donniaquio, Ilaria Gandoglia, Massimo Del Sette, Luca Roccatagliata, Fabrizio Piazza, Matteo Pardini, Rosario Pascarella   +8 more
doaj   +2 more sources

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Frontiers in Neurology, 2022
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD).
Charles G. Withington, R. Scott Turner
doaj   +3 more sources

Validation of an MRI Rating Scale for Amyloid‐Related Imaging Abnormalities [PDF]

Journal of Neuroimaging, 2017
ABSTRACTINTRODUCTIONImmunotherapeutic agents against amyloid beta (Aβ) are associated with adverse events, including amyloid‐related imaging abnormalities with edema and effusion (ARIA‐E). Recently, a magnetic resonance imaging (MRI) rating scale was developed for ARIA‐E detection and classification.
Mike P Wattjes, Frederik Barkhof
exaly   +4 more sources

Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE. [PDF]

J Prev Alzheimers Dis
Amyloid-β-directed monoclonal antibody therapies may lead to amyloid-related imaging abnormalities (ARIA). Clinical trials that formed the basis for the ARIA radiographic severity grading scale adopted by the approved drugs' labels utilized T2* gradient recalled echo (T2*-GRE) images for ARIA-hemorrhagic (ARIA-H) assessment.
Sima DM, Phan TV, Franceschi AM, Gibbs WN, Barkhof F, Scheltens P, Salloway S, Cummings J, Van Hecke W, Smeets D.   +9 more
europepmc   +3 more sources

Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities ...
Alexander Wallace, Oliver Zhou, Minh‐Nguyet Hoang, Gabriella Porter, Claudia Padilla, Cindy Marshall   +5 more
doaj   +2 more sources